|
|
||||||||


* Medical Clinic and Polyclinic II, Julius-Maximilian University of Würzburg, Würzburg, Germany;
Hertie Institute for Clinical Brain Research, Eberhard-Karls University of Tuebingen, Tuebingen, Germany; and
Department of Immunology, Institute for Cell Biology, Eberhard-Karls University of Tuebingen, Tuebingen, Germany
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
T cell recognition of cognate MHC-peptide complexes displayed by an APC results in the formation of an area of close membrane contact between the two cells, known as immunological synapse (IS)3 (5). Once the IS has formed, the T cell stops migrating (6), polarizes its cytoskeleton toward the APC (7, 8), and initiates the movement of the TCR and CD3 to the T cell-APC interface (8, 9). One important feature of the IS is the unidirectional transfer of MHC-peptide complexes (10, 11, 12, 13) along with other molecules, such as CD80 (14), from the APC to the T cell, a phenomenon that has been described as trogocytosis (15). The expression of APC-derived molecules on T cells is biologically significant and has the potential to allow T cells to act as APCs (reviewed by Wetzel and Parker) (16). The Ag specificity of the transfer has been shown to be critical in controlling an immune response, as T cells presenting Ag to each other can induce anergy in vivo (17) or CTL-mediated killing of the presenting T cell (fratricide) (11, 12) in vitro. The capture of specific MHC-peptide complexes from an APC has also been shown in vivo to drive the affinity maturation of a secondary T cell response, by limiting the access of lower affinity T cells to Ag (18). In addition, the transfer of MHC-peptide complexes from APCs to CD4+ T cells has been proposed in the mouse system to stimulate CD8+ CTL responses (19, 20). In contrast to the stimulatory effect observed by mouse Ag-presenting CD4+ T cells (T-APCs), earlier studies have described the specific inhibition or vetoing of Ag-specific CTL responses by CD8+ T cells bearing self-Ag (21, 22, 23, 24).
In this study, we examined the functional consequences of viral epitope presentation by recently activated human CD4+ T cells to the memory herpes virus-specific CD8+ T cells. To address this question, we have used human CD4+ T-APCs by genetically modifying human CD4+ T cells to express model viral Ags. These CD4+ T-APCs were used to stimulate autologous PBMCs from CMV- or EBV-seropositive healthy donors.
Our results suggest that Ag presentation by CD4+ T cells during a viral recall infection results in enhanced stimulation of the CD8+ T cell response.
| Materials and Methods |
|---|
|
|
|---|
Peripheral blood samples were obtained from CMV- and EBV-seropositive donors after obtaining informed consent. PBMCs were isolated from peripheral blood by centrifugation on Ficoll density gradient (Amersham Biosciences).
The retroviral packaging cell line Phoenix-gibbon ape leukemia virus (GALV) previously described (25) was maintained in DMEM (Invitrogen Life Technologies) supplemented with 10% heat-inactivated FCS (Biochrom).
EBV-transformed B lymphoblastoid cell lines (LCLs) positive for HLA-A2 were provided by Dr. S. Stevanovic (Institute for Cell Biology, Tuebingen, Germany) and maintained in RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 10% FCS. When indicated, LCLs were retrovirally transduced with the pLZNGFR-PGK/pp65 construct using nerve growth factor receptor (NGFR) and phosphoglycerate kinase-1 (PGK) promoter by "spin infection" as reported previously (26). In brief, 1 x 106 cells/2 ml of viral supernatant were transferred into each well of a 6-well tissue culture plate (Costar). Following centrifugation at 32°C for 1 h, the cells were incubated at 37°C in 5% CO2 for additional 24 h. The infected LCLs cells were then washed and resuspended in fresh RPMI 1640 supplemented with 10% FCS. Transduced LCLs were analyzed for NGFR expression 7 days postinfection by FACS and were immunoselected on the same day with NGFR beads (Miltenyi Biotec).
CMV pp65-specific CD4+ and CD8+ T cell lines were generated as previously described (27) using the IFN-
secretion assay (Miltenyi Biotec).
Expression vectors
The full-length CMV pp65-coding sequence was amplified by RT-PCR from CMV-infected (strain AD169) fibroblasts, cloned into pcDNA3.1 vector (Invitrogen Life Technologies) and sequenced. LMP-2a cDNA was provided by Miltenyi Biotec. The CMV pp65 gene was modified with the human invariant chain (Ii) sorting signal to direct CMV pp65 Ag into the lysosomal compartment and facilitate presentation in the context of MHC class II. The pcDNA3 vector containing an Ii DNA fragment encoding the first 80 aa was provided by Dr. S. Stevanovic (Institute for Cell Biology, Tuebingen, Germany) The Ii-pp65 fusion gene was constructed by 20 cycles of strand overlap extension PCR with the high fidelity Pwo DNA polymerase.
The pp65, Ii-pp65, or LMP-2a cDNA fragments were cloned into the retroviral vector pLZNGFR-PGK from Dr. S. Riddell (Fred Hutchinson Cancer Research Center, Seattle, WA) under the control of the internal PGK promoter. Upstream of the mouse PGK promoter the human truncated low affinity NGFR is expressed by the 5' long-terminal repeat. The retroviral vector construct pLZNGFR-PGK/pp65, pLZNGFR-PGK/Ii-pp65, or pLZNGFR-PGK/LMP-2a was transfected into the Phoenix-GALV cell line using a calcium phosphate method (28), and supernatant was harvested from puromycin-resistant cells.
Generation of CD40L-activated B cells (CD40-B) and Ag-presenting CD40-B
CD40L-activated B cells (CD40-B) were generated as previously described (26). In brief, PBMCs (8 x 106 cells/well) were cultured on gamma-irradiated (96 Gy) human CD40L-transfected NIH 3T3 cells (t-CD40L) in the presence of IL-4 (4 ng/ml; R&D Systems) and cyclosporin A (CsA; 0.7 µg/ml; Sigma-Aldrich) in 4 ml of IMDM (Invitrogen Life Technologies) supplemented with 10% pooled human serum. The expanding cells were transferred onto freshly prepared t-CD40L cells and fed with cytokine-replenished medium with CsA every 34 days. Retroviral transduction was conducted as previously described (26). In brief, CD40-B cells 2 days after the second stimulation with t-CD40L were centrifuged and resuspended in 1 ml of retroviral supernatant in the presence of 8 µg/ml polybrene (Sigma-Aldrich). Retroviral infection was facilitated by spin infection as reported previously (26). In brief, each cell suspension was transferred into each well of a 6-well tissue culture plate (Costar) and the circumference of the plate was sealed with tape. Following centrifugation at 32°C for 1 h, 4 ng of IL-4 was added and the cells were incubated at 37°C in 5% CO2 for an additional 4 h. The infected CD40-B cells were then resuspended and transferred onto freshly prepared t-CD40L cells and cultured as described. Transduced CD40-B cells were analyzed for NGFR expression on day 12 of culture by FACS and were immunoselected on the same day with NGFR beads (Miltenyi Biotec), to obtain an enriched population of transduced cells. These transduced and immunoselected donor Ag-presenting CD40-B (CD40B-APCs) were expanded in the culture conditions described for 14 days after initial activation and used in stimulation cultures.
Generation of CD4+ T-APCs
Human CD4+ T cells were isolated from PBMCs by negative selection using MACS human CD4+ T cell isolation kit (Miltenyi Biotec) as instructed by the manufacturer. CD4+ T cells were then stimulated with anti-CD3 mAb (30 ng/ml) and irradiated feeder cells as previously described (28) in RPMI 1640 supplemented with 10% human pooled serum and 50 U/ml recombinant human IL-2 (Prolusion; Chiron). On day 2, cells were washed and resuspended in retroviral supernatant supplemented with 50 U/ml recombinant human IL-2 and 8 µg/ml polybrene (Sigma-Aldrich) spun at 1,000 x g for 1 h at 32°C and incubated for 24 h. CD4+ T cells were then washed and cultured in fresh medium containing 50 U/ml recombinant human IL-2. Retrovirally transduced cells were analyzed for NGFR expression on day 12 of their culture by FACS and were then immunoselected by anti-NGFR microbeads to obtain an enriched population of transduced cells. Transduced and NGFR immunoselected donor CD4+ T cells (CD4+ T-APC/pp65, CD4+ T-APC/LMP-2, or CD4+ T-APC/mock) were expanded in the culture conditions described for 14 days after initial activation and used in stimulation cultures.
Where indicated, CMV pp65 CD4+ T cells were cocultured with autologous CD40B-Ii-pp65 cells at a 1:1 ratio at 37°C for 4 h. At the end of the incubation, the CD4+ T cells were purified out of the cell mixture using CD4 microbeads and these cells were used as CD4+ T-APCs (transient Ag expression).
In vitro CTL induction
HLA-A*0201+ or HLA-B*0702+ CD40B-APCs or CD4+ T-APCs were gamma-irradiated (30 Gy) and added to autologous PBMCs at a APC: responder ratio of 1:10 in T cell medium consisting of RPMI 1640 supplemented with 10% heat-inactivated human pool serum. Where indicated, CD3+ T cells were used as responders in the stimulation cultures. One day after stimulation, human IL-2 (recombinant human IL-2; Chiron) was introduced into the cultures at a final concentration of 5 U/ml and every 2 days thereafter. If necessary rapidly growing cells were split into two wells and fed with fresh medium containing 5 U/ml IL-2. On day 7, T cell populations were harvested and assayed.
Cell surface cytometric analysis
For phenotypic characterization of CD40B-APCs and CD4+ T-APCs at day 14 of their culture, cells were stained with mouse mAbs CD70, CD80, CD86, and CD137L all PE-labeled (all from BD Pharmingen).
Tetrameric analyses were performed with HLA-A*0201 tetramers complexed with the peptide NLVPMVATV (CMVpp65/495503) or HLA-B*0702 tetramers complexed with the peptide TPRVTGGGAM (CMVpp65/417426), both derived from CMV pp65, or with HLA-A*0201 tetramers complexed with the peptide CLGGLLTMV (EBVLMP2a/LMP2a426434), derived from EBV LMP2a protein, all PE-labeled (ProImmune), together with a FITC-labeled anti-CD8 and a PerCP-labeled anti-CD3 Ab (BD Pharmingen).
For immunophenotyping of CTLs, FITC-labeled, and PerCP-labeled Abs used against the molecules were CD8, CD45RO, CD27, CD62 ligand (CD62L), and the chemokine receptor CCR7 (all from BD Pharmingen). Isotype-specific negative controls were included in all experiments. Cell samples were analyzed in a FACSCalibur (BD Biosciences), and at least 30,000 events in the gate were collected for each sample and analyzed with the CellQuest Pro software.
Intracellular IFN-
staining
Intracellular cytokine (ICC) staining was performed as recently described (27) with the following modifications. Untransduced or transduced CD40B-APCs and CD4+ T-APCs were mixed with autologous PBMCs or a CMV CD8+ T cell line at a 5:1 or 1:1 ratio, respectively. For cytokine profiling after 7 days of coculture, CTLs were incubated with either untransduced or pp65-transduced LCLs (LCL/pp65) at a 1:1 ratio. In all cases, cells were incubated in the presence of the costimulatory mAbs CD28 and CD49d (2 µg/ml each; both BD Biosciences) for 6 h. Brefeldin A (10 µg/ml; Sigma-Aldrich), was added for the last 5 h of the incubation. Positive controls were performed by stimulating the cells with 0.5 µg/ml PMA and 1 µg/ml ionomycin (both Sigma-Aldrich). Samples were permeabilized (BD Perm; BD Biosciences) and stained with FITC-labeled anti-CD8, PE-labeled anti-IFN-
(BD Biosciences) and analyzed with a FACSCalibur (BD Biosciences) and analyzed as described.
Flow cytometric analysis of trogocytosis
To test the functional consequences of acquisition, CMV pp65-specific CD8+ or CD4+ T cells were incubated with 10 µM CFSE (Molecular Probes) for 10 min at 37°C in serum-free medium, and then washed extensively to remove unbound CFSE. CFSE-labeled CMV pp65-specific CD8+ or CD4+ T cells were cocultured with LCL/pp65 or CD40B/Ii-pp65 cells, respectively, at a 1:1 ratio at 37°C for 4 h. At the end of the 4-h incubation, dead cells were removed from the cell mixture by centrifugation on Ficoll density gradient. CD8+ or CD4+ T cells in the cell mixture were purified by positive selection using CD8 or CD4 microbeads (Miltenyi Biotec).
The capacity of CD8+ or CD4+ T cells that acquired surface molecules to stimulate production of IFN-
was then assessed by ICC. CFSE-labeled CD8+ or CD4+ T cells were incubated with autologous unlabeled CMV-specific CD8+ or CD4+ T cells (CD8+ T cell line >90% tetramer-positive) at a 2:1 ratio for 5 h in the presence of brefeldin A. Samples were permeabilized (BD Perm; BD Biosciences) and stained PE-labeled anti-IFN-
(BD Biosciences) and analyzed in the FACSCalibur.
Cytotoxicity assay
LCL and LCL/pp65 were labeled with 51Cr for 1 h at 37°C. The expanded CD8+ T cell lines (CTLs) were washed and added at various ratios to 5 x 103 per well labeled target cells in U-bottom 96-well plates and incubated for 4 h at 37°C. Then supernatants were counted in a Micro-beta Counter (PerkinElmer). The percentage of specific lysis was determined using the following formula: [(experimental release spontaneous release)/(maximum release spontaneous release)] x 100.
| Results |
|---|
|
|
|---|
To establish a surrogate system for Ag presentation of viral epitopes, we have introduced the whole sequence of viral Ags by retroviral transduction into human activated CD4+ T cells. The transduction efficiency was assessed by the proportion of viable cells expressing NGFR 10 days postinfection by FACS analysis. The percentage of positively stained cells with anti-NGFR mAb was 45% (range 3060%; data not shown). The same day, retrovirally transduced cells were positively selected for NGFR expression (Fig. 1) to obtain a pure population of viral Ag-expressing cells and used as APCs (CD4+ T-APCs). The same method of Ag loading was also used for professional Ag-presenting CD40-B (CD40B-APCs) and served as our positive control for Ag presentation throughout this study.
|
was very similar (12.0 vs 11.2%) when using CD40B-APCs or CD4+ T-APCs (Fig. 3), demonstrating that even if CD4+ T-APCs express lower levels of costimulatory ligands, they are equally potent in inducing Ag-specific production of cytokines as professional APCs.
|
|
The data presented indicate that Ag presentation by CD4+ T cells can activate memory CD8+ T cells to produce cytokines. Yet, the extent of Ag-driven expansion may vary between different APCs. Therefore, PBMCs from HLA-A2- and/or HLA-B7-positive CMV- or EBV-seropositive donors were cocultured with either autologous irradiated CD4+ T-APCs or CD40B-APCs/pp65 in the presence of 5 U/ml IL-2. The expansion of tetramer-specific CD8+ T cells was evaluated by FACS at the end of a 7 day in vitro stimulation cycle. As shown in Fig. 4A, CD40B-APCs and CD4+ T-APCs stimulated a robust Ag-induced expansion of CD8+ T cells.
|
To exclude the possibility that the CD8+ T cell proliferation observed by CD4+ T-APC stimulation is due to Ag uptake by PBMC-derived APCs, we analyzed the proliferation of CD8+ T cells after purification of CD3+ cells and used them as responders in the stimulation cultures. We found that the action of CD4+ T APCs is direct on the CD8+ T cells as the expansion of Ag-specific CD8+ T cells observed when CD3+ T cells were used as responders was equivalent to that with whole PBMC responders (Fig. 4C). We next examined the CD4+ T cell APC potency. APC titration experiments revealed similar potency of CD4+ T-APCs and professional APCs (CD40BB-APCs) in stimulating the expansion of memory Ag-specific CD8+ T cells (Fig. 4D). Taken together, these data not only demonstrate that the immunostimulatory effect of CD4+ T-APCs is Ag-specific, but also that CD4+ T-APCs are as potent as professional APCs in inducing CD8+ T cell responses.
Ag-specific CTLs are not rendered hyporesponsive following interactions with CD4+ T-APCs
Stimulation of T cells with APCs, in the absence or low levels of costimulatory ligands, can result in anergy of the stimulated T cells. To assess the functional status of the CD4+ T-APC-induced CD8+ T cells, we determined their Ag-specific cytolytic activity by a 51Cr release assay on day 7 of their ex vivo expansion (Fig. 5A). The CD4+ T APC expanded CD8+ T cells lysed HLA-A2-positive pp65-transduced LCLs in a dose-dependent manner. Low background killing was observed by parental nontransduced LCLs, indicating that the killing activity of these CTLs is CMV pp65-specific. Effector function of the generated CD8+ T cells was further evaluated by analyzing the cytokine production of the expanded CMV-specific CD8+ T cells upon activation with APCs. An intracellular IFN-
assay was performed, using as responders the expanded CD8+ T cells, derived after a 7-day in vitro stimulation with either CD4+ T-APCs or CD40B-APCs, against parental or pp65-transduced LCLs. The CD4+ T-APCs-induced CD8+ T cells were as efficient as CD40B-APCs-induced CTL in their capacity to produce IFN-
when restimulated with Ag (Fig. 5B). This finding indicates that the CD4+ T-APCs-induced CD8+ T cells can produce effector cytokines upon Ag rechallenge.
|
|
During the formation of the IS, MHC-peptide complexes travel from the APCs to T cells allowing the latter to act as APCs (T-APCs). To address whether Ag-specific T cells upon activation can function as APCs for responder CD8+ T cells, we examined the capacity of activated Ag-specific CD8+ T cells to acquire antigenic peptides, while interacting with other CD8+ T cells with the same specificity. For these experiments, CMVpp65-specific CD8+ T cells were labeled with CFSE (referred to as CD8+ T-APCs) and cultured for 4 h with LCL targets expressing the CMV pp65 Ag in form of retroviral vector (LCLs/pp65). At the end of the incubation period with targets, the CD8+ T-APCs were purified from the cell mixture using CD8 magnetic beads. These cells were subsequently cultured together with autologous CMVpp65-specific CD8+ T cells. After 6 h, IFN-
production was determined by ICC staining in the CFSE-negative fraction. As shown in Fig. 7A, CFSE-negative CMVpp65-specific CD8+ T cells produced IFN-
upon recognition of the acquired Ag displayed by the CFSE-positive fraction. By contrast, the same cells did not produce IFN-
in response to the CFSE-labeled cells that were incubated with LCLs expressing the mock retroviral vector (Fig. 7A, left).
|
We next sought to address whether Ag trogocytosed by CD4+ T cells would enable them to stimulate the expansion of memory CD8+ T cells. A direct comparison of Ag-specific CD8+ T cell expansion using either continuous (retrovirally transduced) or transient (after trogocytosis) Ag presentation by CD4+ T-APCs is shown in Fig. 7C. The analysis revealed that activated CD4+ T cells that have trogocytosed Ag are also able to elicit a specific CD8+ T cell response, although to a lesser extent that CD4+ T cells, which are stably transduced with the Ag. Thus, acquisition of antigenic material by Ag-specific CD4+ cells during contact with APCs, licenses T cells to act themselves as APCs and stimulate an Ag-specific CD8+ T cell response.
| Discussion |
|---|
|
|
|---|
There is considerable evidence in support of the notion that both activated 
T cells (16, 29) and activated 
T cells (30) can function as APCs (so-called T-APCs) and thereby affect the activities of other T cells. Several studies have indicated that TCR ligation plays a central role in the generation of the T-APC phenotype. Biosynthesis of MHC and costimulatory molecules or acquisition of intact MHC complexes from APCs represent two Ag-dependent mechanisms that couple TCR recognition with T cell expression of MHC molecules loaded with specific peptides. Both pathways enable T cells to use cognate receptor specificity, guiding the specificity of Ag presentation. However, their role in the immune response remains a matter of debate because of the wide variety of cell types and experimental settings used, though sometimes generating conflicting results (17, 31, 32, 33, 34, 35).
Ag presentation by T cells to activated Ag-specific T cells typically results in down-regulatory signals by inducing either apoptosis (21, 22, 23, 24, 31, 32) or clonal anergy (17, 31) and desensitization of responders in vitro (34). By contrast, other studies have documented that when the responding T cells are freshly isolated, then the T-APCs can induce IL-2 production and proliferation among naive responder T cells (33, 35). We show in this study that human CD4+ T cells genetically modified to express viral Ags can function as APCs to stimulate herpes virus-specific CTL responses. The efficiency of the direct Ag presentation was evidenced by the numerical expansion and proliferation of CMV pp65 and LMP2a tetramer-positive CD8+ T cells in response to irradiated CMV pp65+ and LMP2a+ CD4+ T-APCs, respectively, in vitro. Consistent with our finding that CD4+ T-APCs express multiple costimulatory ligands (although to a lesser degree than professional APCs) is the fact that CD4+ T-APC-elicited CMV pp65 and LMP2a CD8+ responders are functional with respect to cytokine production and cytolytic killing. Interestingly, comparative studies revealed the same potency when using professional APCs, namely CD40-B cells, identically Ag-loaded.
The immunosuppressive effects of Ag presentation by T cells described in other studies may be related to high expression of CTLA-4 on the T cell lines and clones that were used as APCs, (36) or may relate to differences in bidirectional signaling between cell lines of the same specificity and freshly isolated cells. By contrast, unidirectional presentation has been shown to lead to a significant proliferative response (31). Moreover, depending on the state of activation of the reactive T cell line, stimulation with T-APCs may induce anergy or proliferation (37). In this study, we demonstrate that in contrast to activated T cell lines and clones, freshly activated CD4+ T cells can stimulate the expansion of autologous memory CD8+ T cells. Furthermore, by using class I tetramers to identify and enumerate the Ag-specific CTLs, we were able to exclude a veto cell inactivation of Ag-specific antiviral CD8+ T cells in our system. In contrast to earlier studies using CD8+ T cells as APCs (22, 23, 24), we found that CD4+ T-APCs have no veto activity. These results are in agreement with studies that have shown that Ag-specific secondary CTL responses are resistant to veto cell suppression in vitro (21).
The stimulation of the CD8+ T cell response achieved in this study, in contrast to peptide-pulsed T cells previously used as T-APCs, may be related to the duration of Ag presentation. We have designed an alternative and more physiological system for Ag delivery to CD4+ T cells than peptide pulsing. Retroviral transduction of CD4+ T-APCs with viral Ags provides a stable and continuous intrinsic MHC class I-peptide complex supply, thus enabling longer lasting Ag presentation to CD8+ T cells than peptide-pulsed T-APCs. We reason that the induction of immunogenic or tolerogenic activity by CD4+ T-APCs reflects differences in the efficiency of Ag presentation.
In addition to endogenous expression of MHC and costimulatory molecules by T cells, several reports have described the unidirectional cell surface transfer of these molecules from APCs to both CD4+ and CD8+ T cells through the IS (10, 11, 12, 15, 17). This phenomenon, which has been called trogocytosis, is attracting increasing attention due to its potential physiological relevance. Studies in the mouse system have demonstrated that CD8+ T cells acquire MHC class I-peptide complexes from APC, and when these cells present Ag to other CTLs of the same specificity, fratricidal effects are produced, resulting in the down-regulation of CTL responses (11, 13). Fratricide killing has been proposed to account for the state of T cell exhaustion that results after exposure to high doses of Ag (11). Similarly, Tsang and coworkers (17) reported that previously activated mouse CD4+ T cells acquired MHC class II molecules and presented Ag to themselves, resulting in an increase in apoptosis and in the induction of hyporesponsiveness.
Our results show a completely different picture when human activated CMVpp65-specific CD8+ or CD4+ T cells acquired antigenic peptides from LCL/pp65 and CD40B/Ii-pp65, respectively, after coculture. We have shown that both CD8+ and CD4+ T cells can present the acquired material to responder CD8+ T cells in vitro. The acquired molecules on both CD4+ and CD8+ T cells were functional, leading to the activation of the responder CMVpp65 CD8+ T cells as determined by IFN-
production in a 6-h assay.
It has been suggested that the fratricidal effect observed in previous studies may not be physiological because it only occurs when an extremely high concentration of MHC class I-restricted antigenic peptide is added externally to the target cell. The most obvious explanation for the immunostimulatory effect observed in our study is the lower and more physiological concentration of the endogenously processed peptides, presented by APCs, as it would occur during natural infection. In support of this notion, Hudrisier et al. (38) have shown that distinct thresholds for CTL function correlate with differences in the amount of Ag trogocytosed, and fratricide could only be detected at very high Ag concentrations.
Two recent mouse studies have re-examined the physiological relevance of APC molecule acquisition by CD4+ T cells. Kennedy et al. (19) demonstrated the ability of Th cells to act as APCs to present MHC class I-restricted epitopes to naive cells to generate central memory CTLs. In addition, Xiang et al. (20) demonstrated that T cells have the capacity to recruit other T cells and act as helper cells for the generation of effector CTLs. The authors (20) suggest that the presence of antigenic material on these Th cells might provide a simple way of imparting some specificity on help delivery, which might be particularly significant when there is need to expand T cell clones specific for a relatively rare Ag.
In agreement with these two reports, we extend the findings to the human system and demonstrate that activated CD4+ T cells capture antigenic material from professional APCs through the IS to enable themselves to act as APCs for the effective stimulation and expansion of memory CD8+ T cell responses in vitro.
We therefore hypothesize that during infection CD4+ T cells in contact with activated professional APCs in the lymph node can acquire Ags and present them to neighboring virus-specific CD8+ T cells. Ag presentation by CD4+ T cells might be a mechanism to amplify the effector/memory CD8+ T cell response for faster control of a viral rechallenge.
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by Grant LSHB-CT-2004-503319 from Allostem and SFB-479/TP-C12 from Deutsche Forschungsgemeinschaft. ![]()
2 Address correspondence and reprint requests to Eleni Adamopoulou, Medical Clinic and Polyclinic II, Julius-Maximilians University of Würzburg, Röntgernring 11, D-97070 Würzburg, Germany. E-mail address: eleni.adamopoulou{at}mail.uni-wuerzburg.de ![]()
3 Abbreviations used in this paper: IS, immunological synapse; ICC, intracellular cytokine; NGFR, nerve growth factor receptor; CD62L, CD62 ligand; T-APC, Ag-presenting T cell; CD40-B, CD40L-activated B cell; CD40B-APC, Ag-presenting CD40-B cell; CsA, cyclosporin A; GALV, gibbon ape leukemia virus; LCL, lymphoblastoid cell line; PGK, phosphoglycerate kinase; Ii, invariant chain; t-CD40L, CD40L-transfected NIH 3T3 cell. ![]()
Received for publication May 5, 2006. Accepted for publication February 9, 2007.
| References |
|---|
|
|
|---|

T cells. Science 309: 264-268. This article has been cited by other articles:
![]() |
J. Diekmann, E. Adamopoulou, O. Beck, G. Rauser, S. Lurati, S. Tenzer, H. Einsele, H.-G. Rammensee, H. Schild, and M. S. Topp Processing of Two Latent Membrane Protein 1 MHC Class I Epitopes Requires Tripeptidyl Peptidase II Involvement J. Immunol., August 1, 2009; 183(3): 1587 - 1597. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Umeshappa, H. Huang, Y. Xie, Y. Wei, S. J. Mulligan, Y. Deng, and J. Xiang CD4+ Th-APC with Acquired Peptide/MHC Class I and II Complexes Stimulate Type 1 Helper CD4+ and Central Memory CD8+ T Cell Responses J. Immunol., January 1, 2009; 182(1): 193 - 206. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |